Pinpoint Genomics Eyes Piece of Lung Cancer Dx Market with Prognostic NSCLC Assay | GenomeWeb

By Tony Fong

NEW YORK (GenomeWeb News) – Genetic test maker Pinpoint Genomics has moved into commercialization phase with the launch of its first product, a prognostic test for non-small cell lung cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.